S.B. No. 1525 amends the Texas Insurance Code to enhance coverage for prescription drugs related to the treatment of neurodegenerative diseases, alongside autoimmune diseases and certain blood disorders. The bill modifies the heading of Subchapter N, Chapter 1369, to include "NEURODEGENERATIVE DISEASES AND CERTAIN BLOOD DISORDERS." Additionally, it revises Section 1369.654 to limit health benefit plan issuers from requiring more than one prior authorization annually for prescription drugs prescribed for autoimmune diseases, neurodegenerative diseases, hemophilia, or Von Willebrand disease.

Furthermore, the bill introduces a provision allowing health benefit plan issuers to require prior authorization for new prescription drugs specifically prescribed for neurodegenerative diseases. The changes will apply only to health benefit plans that are delivered, issued for delivery, or renewed on or after January 1, 2026, while plans renewed before this date will continue to follow the previous law. The act is set to take effect on September 1, 2025.

Statutes affected:
Introduced: Insurance Code 1369.651, Insurance Code 551.003 (Insurance Code 1369, Insurance Code 551)
Senate Committee Report: Insurance Code 1369.654 (Insurance Code 1369, Insurance Code 551)
Engrossed: Insurance Code 1369.654 (Insurance Code 1369, Insurance Code 551)